Evadol2 mg

Evadol is an injectable estrogen ester used mainly in postmenopausal hormone therapy. Established, FDA-approved indications include:

• Moderate to severe vasomotor symptoms (hot flashes and night sweats) associated with menopause.
• Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, although low-dose topical or vaginal estrogen products are generally preferred when systemic therapy is not otherwise needed.
• Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.
• Palliative treatment of advanced, androgen-dependent carcinoma of the prostate in men (not curative), as adjunct hormonal therapy.

Evadol is also used as a component of certain combined estrogen-progestin hormone replacement or contraceptive regimens; it is not intended for use as a contraceptive on its own.

Evadol is not indicated for the prevention of cardiovascular disease or dementia and should not be used for this purpose.

Each formulation of Estradiol Valerate is typically supplied as a sterile injectable solution in an oil-based vehicle (e.g., castor oil), commonly available in strengths such as 10 mg/mL, 20 mg/mL, or 40 mg/mL. Exact composition, strength, and excipients vary by manufacturer and country of registration; refer to the specific product's package insert for confirmed details.

Evadol is a synthetic ester of the natural human estrogen 17β-estradiol. After intramuscular injection, it is slowly hydrolyzed to release free estradiol, providing a sustained, long-acting source of estrogen. It belongs to the estrogen class of hormonal medicines and is used mainly to replace declining estrogen levels in postmenopausal women or women with ovarian insufficiency, and as palliative therapy in advanced prostate cancer.

Evadol belongs to the therapeutic class of natural/synthetic estrogens, used in hormone replacement therapy (HRT) and, in combination with a progestin, in some hormonal contraceptive regimens.

Estradiol Valerate is a prodrug ester that is hydrolyzed after intramuscular injection to release free estradiol, the principal biologically active human estrogen. Estradiol binds to estrogen receptors in target tissues (uterus, vagina, breast, pituitary, hypothalamus, bone) and modulates transcription of estrogen-responsive genes, restoring estrogenic activity in estrogen-deficient women. It reduces vasomotor symptoms, maintains vaginal and urogenital epithelium, and helps preserve bone mineral density.

Pharmacokinetics

• Absorption: Slowly and steadily absorbed from the intramuscular oily depot over roughly 2-4 weeks.
• Metabolism: Hydrolyzed to estradiol, then metabolized primarily by hepatic CYP3A4 to estrone and estriol and their conjugates.
• Excretion: Excreted mainly in urine as glucuronide and sulfate conjugates, with some biliary/fecal elimination.

Evadol injection is for deep intramuscular injection only, given into the upper outer quadrant of the gluteal muscle using aseptic technique. It must not be given intravenously. The solution should be visually inspected for particulate matter or discoloration before use; it should appear clear to pale yellow. Dry needles and syringes should be used, as moisture can cause cloudiness. Injection sites should be rotated with repeated dosing.

Evadol is partly metabolized via hepatic CYP3A4, so drugs affecting this enzyme can alter its blood levels and effects:

• CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's Wort) may reduce the effectiveness of Evadol and increase breakthrough bleeding.
• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice) may increase estradiol levels and the risk of estrogen-related side effects.
• Thyroid hormone replacement: Evadol increases thyroid-binding globulin, which may increase the required dose of thyroid hormone in patients on replacement therapy.
• Corticosteroids: Estrogens may increase corticosteroid-binding globulin, potentiating co-administered corticosteroids.
• Anticoagulants: Estrogens can alter coagulation parameters and may reduce the effect of drugs such as warfarin; monitoring is advised.

Always inform your physician of all medicines being taken before starting Evadol.

Evadol may cause the following adverse effects:

Common

• Breast tenderness, enlargement, or pain
• Nausea, bloating, abdominal cramps
• Headache, migraine
• Irregular vaginal bleeding or spotting
• Fluid retention, mild weight change
• Mood changes, irritability

Less common but serious

• Venous thromboembolism (deep vein thrombosis, pulmonary embolism)
• Myocardial infarction or stroke
• Gallbladder disease
• Cholestatic jaundice
• Hypertension
• Increased risk of endometrial and breast cancer with prolonged use (see Precautions and Warnings)

Patients should seek prompt medical attention for chest pain, sudden shortness of breath, leg swelling/pain, sudden severe headache, vision changes, or signs of jaundice while using Evadol.

Evadol is contraindicated in known or suspected pregnancy. There is no indication for its use during pregnancy, and it should be discontinued immediately if pregnancy occurs or is suspected during treatment.

Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of breast milk, and detectable amounts pass into breast milk. Evadol should generally be avoided during breastfeeding; if hormone therapy is needed, it should be used only after consultation with a physician, who will weigh potential benefits against possible risks to the infant.

Evadol carries important warnings requiring careful patient selection and monitoring:

• Endometrial cancer: Unopposed estrogen use in women with an intact uterus increases the risk of endometrial hyperplasia and cancer; adding a progestin substantially reduces this risk. Report abnormal vaginal bleeding promptly.
• Cardiovascular risk: Increased risk of myocardial infarction, stroke, and venous thromboembolism, particularly with prolonged use; use the lowest effective dose for the shortest duration needed and discontinue promptly if a thromboembolic or vascular event occurs.
• Breast cancer: Long-term estrogen therapy is associated with an increased risk of breast cancer; regular clinical breast examination and mammography are recommended.
• Gallbladder disease, hypertriglyceridemia, hepatic impairment, hypertension, hypothyroidism, fluid-retaining conditions (cardiac/renal disease), and hypercalcemia: Use with caution and monitor closely, as Evadol can worsen these conditions.
• Visual disturbances: Discontinue if sudden loss of vision, proptosis, diplopia, or migraine occurs, and evaluate for retinal vascular thrombosis.
• Not for cardiovascular or dementia prevention: Evadol should not be used to prevent heart disease, stroke, or dementia.
• Consider discontinuing 4-6 weeks before elective surgery associated with increased thromboembolic risk, or during prolonged immobilization.

Overdose of Evadol may cause nausea, vomiting, breast tenderness, abdominal bloating, and withdrawal bleeding in women. Serious acute toxicity has not been well documented, but any suspected overdose should be treated as a medical emergency. If overdose is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive, as there is no specific antidote.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze.

Pediatric Use

Safety and efficacy of Evadol in children have not been established, except in defined situations such as induction of puberty under specialist endocrinology supervision. Prolonged high-dose use may accelerate epiphyseal closure and should be monitored with periodic bone age assessments.

Geriatric Use

Data on Evadol use in women 65 years and older are limited. Increased risk of dementia and cardiovascular events has been observed with estrogen therapy in older postmenopausal women; use with caution at the lowest effective dose.

Hepatic/Renal Impairment

Evadol is contraindicated in patients with active liver disease or severe hepatic impairment. No well-established dose adjustment is defined for renal impairment; use with caution and monitor for fluid retention.

The duration of Evadol therapy should be individualized. For menopausal symptom relief, it is generally used at the lowest effective dose for the shortest duration consistent with treatment goals, with periodic attempts (every 3-6 months) to taper or discontinue therapy and reassess the need for continued treatment. For hypoestrogenism due to hypogonadism or ovarian failure, and for palliative prostate cancer therapy, duration is determined by the treating physician based on clinical response and ongoing risk-benefit assessment.

Estradiol Valerate belongs to the drug class of estrogens (steroid hormones), specifically a long-acting injectable estrogen ester used in hormone replacement therapy.

Estradiol Valerate is hydrolyzed in vivo to 17β-estradiol, which binds to nuclear estrogen receptors (ERα and ERβ) in target tissues. This receptor complex binds estrogen-response elements on DNA, regulating gene transcription that restores or maintains normal estrogenic effects, including relief of vasomotor symptoms, maintenance of vaginal and urinary tract epithelium, and support of bone density in estrogen-deficient states.

X — systemic estrogens including Evadol fall under the legacy FDA pregnancy category X and are contraindicated in pregnancy.

The safety and effectiveness of Evadol in children have not been established for general use. It may be used off-label in specialized pediatric endocrinology settings (e.g., pubertal induction in girls with hypogonadism) under close specialist supervision, with periodic monitoring of growth and bone age, since high-dose or prolonged use can accelerate epiphyseal closure and affect final adult height.